Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin target attainment in general ward patients
NL-OMON25299Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ciprofloxacin in bacterial disease, urinary tract infection (UTI), pneumonia and 3 more, sponsored by Amsterdam University Medical Center. Primary endpoint: AUC0-24/MIC. Started Jan 2018; status: active, not recruiting.
02
Drugs
ciprofloxacin
03
Conditions
bacterial diseaseurinary tract infection (UTI)pneumoniaWound infection (WI)sepsis
Beyond the preview
Go deeper on NL-OMON25299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25299.